Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Next Previous
Drug Profile

Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: 5-aminolevulinic acid; ALA; ALA PDT; Aminolevulinic acid hydrochloride

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata
  • Phase III Glioma
  • Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Phase I/II Acne vulgaris
  • No development reported Basal cell cancer

Most Recent Events

  • 19 Aug 2025 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase III trial in Glioma (Diagnosis) in China (PO) (NCT06417281)
  • 19 Jun 2024 Phase-III clinical trials in Glioma (Diagnosis) in China (PO) (NCT06417281)
  • 17 May 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans to initiates a phase III trial for Glioma (Diagnostic, Newley-diagnostic, Metastatic disease) in China (PO) (NCT06417281)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top